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Kidney International (2021) 99, 59–67I n sub-Saharan Africa, glomerular disease, specificallynephrotic syndrome (NS), is the leading cause of chronickidney disease and end-stage kidney disease in children.1–3
The prevalence of NS is estimated at 2 to 7 per 100,000 chil-
dren worldwide,1 and it is one of the more common causes
of pediatric kidney disorders in Africa. Despite limited reports
from Nigeria and Sudan,2–4 the overall incidence of NS in Af-
rica is unknown. Among the 54 African countries, only 17 have
information on the burden of childhood NS, indicating sub-
stantial under-reporting.5 The absence of large-scale studies
of NS in Africa addressing key questions of incidence and out-
comes reflects the limited resources available including medical
records, diagnostics, medications, and clinical and research
staff. Based on historical data, black children with NS have rela-
tively higher steroid resistance rates than children of other eth-
nicities throughout Africa,6–8 and focal segmental
glomerulosclerosis is the most common histopathologic diag-
nosis.9 Recent studies from several regions in Nigeria recently
documented high and increasing rates of steroid
responsiveness.5,10,11
Treatment guidelines for NS developed in Western coun-
tries are not always applicable to low-resource settings,4 often
failing to consider economic issues impacting clinical care,
such as access to medications, drug level monitoring, and
kidney biopsy.5
The Human Hereditary and Health in Africa–Kidney
Disease Research Network (H3A-KDRN), was established to
conduct genomic studies of kidney disease in sub-Saharan
Africa.1259
Table 1 | Variability in clinical practice among 30 practicing nephrologists across sub-Saharan Africa





Age of child, y 18 30 (100) 18 (12–18) 18
Steroid (prednisone)a treatment
Treatment at initial presentation
Total duration of prednisone, wk 12 12 30 (100) 12 (8–44) 12–16b
Duration of daily prednisone, wk 4–6 4–6 30 (100) 6 (4–30) 6
Duration of alternate-day prednisone, wk 8–20 4–6 30 (100) 6 (0–20) 6
Maximum daily dose of prednisone, mg 60 60 30 (100) 60 (40–100) 60
Maximum alternate-day dose of prednisone, mg 40 40 30 (100) 40 (20–100) 40
Treatment of relapses
Maximum daily dose of prednisone, mg 60 — 30 (100) 60 (10.0–100) 60
Maximum alternate-day dose of prednisone, mg 40 — 30 (100) 40 (40.0–40) 40
Steroid-sparing treatmentc
Levamisole (n ¼ 12)d
Prescribed dose on alternate days, mg/kg 2.5 — 12 (40)d 2.5 (1.5–4) 2.5
Minimum duration of treatment, mo 12 — 12 (2–24) 6
Maximum duration of treatment, mo — — 24 (6–36) 24
Cyclophosphamide (n ¼ 17)d,e
Prescribed dose, mg/kg per day 2 N/A 17 (57)d 2 (2–20) 2
Minimum duration of treatment, wk 8 8 (8–32) 12
Maximum duration of treatment, wk 12 12 (4–72) 12
Calcineurin inhibitors
Cyclosporine (n ¼ 14)d
Prescribed dose in mg/kg per day (divided into 2 doses) 4–5 3–5 14 (47)d 3 (0.5–15) 3–5
Minimum duration of treatment, mo 12 6f 6 (3–24) 6
Maximum duration of treatment, mo — 24 24 (6–48) 24
Monitoring of drug levels during therapy — Weekly, then 1–3 mo
Minimum target trough level, ng/ml — 80 10 (33) 100 (20–100) 50
Maximum target trough level, ng/ml — 120 100 (100–200) 100
Tacrolimus (n ¼ 8)d
Prescribed dose in mg/kg per day (divided into 2 doses) 0.1 0.1–0.2 8 (27)d 0.1 (0.05–0.5) 0.1 – 0.2
Minimum duration of treatment, mo 12 6f 12 (3–24) 6
Maximum duration of treatment, mo — 24 24 (12–48) 24
Monitoring of drug levels during therapy — Weekly, then 1–3 mo
Minimum target trough level, ng/ml — 4 7 (24) 5 (3–5) 5
Maximum target trough level, ng/ml — 8 8 (8–10) 8
Mycophenolate (n ¼ 11)d
Prescribed dose in mg/m2 per day (divided into 2 doses) 1200 1200 11 (37)d 1200 (800–1500) 600
Minimum duration of treatment, mo 12 12 6 (3–24) 6
Maximum duration of treatment, mo — 24 (6–60) 24
Monitoring of white blood cell during treatment — 10 (33)
Frequency of monitoring white blood cells, wk — 4 (1–12) 4
IPNA, International Pediatric Nephrology Association; KDIGO, Kidney Disease: Improving Global Outcomes; N/A, not available; —, not available in the KDIGO guidelines.
aAlso may be referred to as prednisolone in some countries.
bThis accounts for a 6-week daily duration, a 6-week alternate-day duration, and an additional 4 weeks of tapering.
cOnly 22 physicians responded to this portion of the survey. However, all percentages listed are based on a denominator of 30.
dResponses were available only from clinical sites that had access to corresponding steroid-sparing medication.
eOne clinical center prescribes cyclophosphamide intravenously. The consensus was to prescribe intravenous cyclophosphamide at 500 mg/m2 per dose, given monthly for 4
months.
fCalcineurin inhibitors should be stopped if partial remission is not achieved at 6 months (grade B, moderate recommendation, IPNA guideline).
po l i c y fo rum C Esezobor et al.: Childhood nephrotic syndrome in sub-Saharan AfricaThe network also provides a platform for capacity
building and development of consensus clinical guide-
lines that address variability in care of those with
chronic kidney disease. Our aim was to use the network
to assess practice variation in management of NS among
centers participating in H3A-KDRN, and generate a
consensus statement on the management of childhood
NS in sub-Saharan Africa using the modified Delphi
approach.60RESULTS
The working group included 30 pediatric and/or adult ne-
phrologists from 18 clinical sites across 6 countries who
completed a survey on NS management in children/adoles-
cents and participated in the consensus meeting
(Supplementary Figure S1).
There was significant variation in clinical practice, specif-
ically the hospital policy on age of a child, dose and duration
of prednisone, and choice of steroid-sparing agents (Table 1).Kidney International (2021) 99, 59–67
Table 2 | Summary of the consensus agreement compared with the KDIGO glomerulonephritis and IPNA guidelines
KDIGO IPNA Consensus agreement
Definitions of nephrotic syndrome in children
Relapse: uPCR $2000 mg/g ($200 mg/mmol)
or $3þ protein on urine dipstick for
3 consecutive days
Relapse: urine dipstick $3þ
protein for 3
consecutive days or
uPCR $2000 mg/g ($200
mg/mmol)
Relapse: $2þ proteinuria for 3 consecutive days on an
early morning urine or $2þ proteinuria with edema
Remission: uPCR <200 mg/g (<20 mg/mmol)
or <1þ of protein on urine dipstick for
3 consecutive days
Remission: uPCR <200 mg/g
(<20 mg/mmol)
or <1þ of protein on urine
dipstick for 3 consecutive days
Remission: trace/negative for at least 3 consecutive days
on urine dipstick only
KDIGO guideline
number KDIGO recommendation statement IPNA guidelines Summary of the consensus agreement
3.1.1 We recommend that corticosteroid therapy
(prednisone or prednisolone) be given for
at least 12 wk (1B)
Prednisone therapy for 10–12 wk We agreed on the total duration of
prednisone therapy for up to 16 wk to
account for tapering of steroids, similar to
KDIGO guidelines
3.1.1.1 We recommend that oral prednisone be
administered as a single daily dose (1B)
starting at 60 mg/m2 per day or 2 mg/kg
per day to a maximum of 60 mg/d (1D)
The initial treatment of children with
idiopathic NS usually comprises oral
prednisone 60 mg/m2 per day or 2 mg/kg
per day (maximum, 60 mg/d)
We agreed that oral prednisone be
administered for the initial episode of NS
as a single daily dose at 60 mg/m2 per day,
up to a maximum of 60 mg
3.1.1.2 We recommend that daily oral prednisone
be given for 4–6 wk (1C) followed by
alternate-day medication as a single daily
dose starting at 40 mg/m2 or 1.5 mg/kg
(maximum, 40 mg on alternate days) (1D)
and continued for 2–5 mo with tapering of
the dose (1B)
Oral prednisone is given for 4–6 wk
followed by 40 mg/m2 or 1.5 mg/kg per
dose on alternate days for another 4–6 wk
We agreed on daily oral prednisone at 60
mg/m2 per day up to a maximum of 60 mg
as a single daily dose for 6 wk followed by
40 mg/m2 prednisone as a single morning
dose on alternate days for another 6 wk
and thereafter tapered at the rate of 10
mg/m2 per week to 5 mg on alternate days
The dose of the prednisone should be
discontinued once tapered down to 5 mg
on alternate days
Total duration of therapy will be 16 wk
3.2.1.1 We suggest that infrequent relapses of
SSNS in children be treated with a single-
daily dose of prednisone 60 mg/m2 or 2
mg/kg (maximum, 60 mg/d) until the child
has been in complete remission for at least
3 days (2D)
N/A We agreed, consistent to KDIGO guidelines,
60 mg/m2 (maximum, 60 mg/d) oral
prednisone for relapse daily until remission
(urine dipstick trace/negative for at least 3
consecutive days)
3.2.2.1 We suggest that relapses in children with
FR or SD SSNS be treated with daily
prednisone until the child has been in
remission for at least 3 days, followed by
alternate-day prednisone for at least 3 mo
(2C)
N/A We agreed for relapse to be treated with
oral prednisone 60 mg/m2 (maximum, 60
mg/d) daily until remission (urine dipstick
trace/negative for at least 3 consecutive
days)
Once in remission, decrease prednisone to
40 mg/m2 per day (maximum, 40 mg/d) on
alternate days for 1 wk, then taper by 10
mg/m2 per day per week to complete a
total of 4 wk
Similar to the initial course, all doses to be
rounded up to account for 5-mg tablets
3.3.2 We recommend that alkylating agents,
cyclophosphamide, or chlorambucil be
given as corticosteroid-sparing agents for
FR SSNS (1B)
We suggest alkylating agents,
cyclophosphamide, or chlorambucil be
given as corticosteroid-sparing agents for
SD SSNS (2C)
N/A We agreed to use levamisole as the first-
line steroid-sparing agent if available and
then cyclophosphamide
3.4.1 Indications for kidney biopsy in children
with SSNS are as follows (not graded): late
failure to respond after initial response to
corticosteroids; a high index of suspicion
Quantification of proteinuria by urine
protein/creatinine ratio in either first
morning urine or 24-hour urine sample at
least once before defining SRNS and/or
Indications for kidney biopsy in children
with SSNS: late-onset steroid resistance;
suspicion of a secondary cause of disease;
assessment of CNI nephrotoxicity; NS
(Continued on following page)
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Table 2 | (Continued) Summary of the consensus agreement compared with the KDIGO glomerulonephritis and IPNA guidelines
KDIGO guideline
number KDIGO recommendation statement IPNA guidelines Summary of the consensus agreement
for a different underlying pathology;
decreasing kidney function in children
receiving CNIs
starting alternate immunosuppression
Use this baseline value for assessing
subsequent response (Grade A, strong
recommendation)
diagnosis before the age of 1 year or older
than the age of 12 yr
4.1.1 We suggest a minimum of 8 wk of
treatment with corticosteroids to define
steroid resistance (2D)
Lack of complete remission within 4 wk of
treatment with prednisone at standard
dose
If no remission is achieved by 6 wk, the
diagnosis of SRNS is confirmed
We agreed to define steroid resistance as
lack of response to daily prednisone after 8
wk of therapy consistent with definition in
KDIGO guidelines
4.1.2 The following are required to evaluate the
child with SRNS (not graded): a diagnostic
kidney biopsy; evaluation of kidney
function by GFR or eGFR; quantitation of
urine protein
A renal biopsy in all children diagnosed
with SRNS, except in known infection or
malignancy-associated secondary disease
or potentially in patients with familial and/
or syndromic cases or genetic causes of
SRNS (grade A, strong recommendation)
Genetic testing results (grade B, moderate
recommendation) as soon as possible,
ideally within the 2-wk confirmation period
In low-resource countries where genetic
and/or histopathology assessment is not
available, immediate immunosuppressive
treatment with CNI may be started
If CNIs are not available, intravenous or oral
cyclophosphamide may be started
We agreed to evaluate the child with SRNS
with the following: percutaneous kidney
biopsy to ascertain histopathology and
guide treatment (the light microscopy with
special immunohistochemistry stains if
immunofluorescence and electron
microscopy are not available); evaluation of
kidney function with serum creatinine
measurement to estimate GFR;
quantification of uPCR instead of the 24-
hour urine collection
Prescribe CNI if biopsy not readily available
in the country
4.2.1.1 We suggest that CNI therapy be continued
for a minimum of 6 mo and then stopped if
a partial or complete remission of
proteinuria is not achieved (2C)
We suggest a minimum treatment period
of 6 mo to determine the response to CNIs
(grade B, weak recommendation)
We recommend that CNIs should be
stopped if partial remission is not achieved
at 6 mo (grade B, moderate
recommendation)
We agreed to use CNI therapy for SRNS for
a minimum of 6 mo to assess response
4.2.1.2 We suggest CNIs are continued for a
minimum of 12 mo when at least a partial
remission is achieved by 6 mo (2C)
If complete remission is achieved, CNI
dosages should be reduced to the lowest
dosage required to maintain remission
We also suggest considering
discontinuation of CNIs after 12–24 mo in
these patients to reduce the risk of
nephrotoxicity (grade C, weak
recommendation)
We agreed CNI be continued for up to 2 yr
when at least partial response is achieved
by 6 mo
CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; FR, frequently relapsing; IPNA, International Pediatric Nephrology Association; KDIGO, Kidney Disease:
Improving Global Outcomes; N/A, not available; NS, nephrotic syndrome; SD, steroid-dependent; SRNS, steroid-resistant nephrotic syndrome; SSNS, steroid-sensitive nephrotic
syndrome; uPCR, urine protein to creatinine ratio.
po l i c y fo rum C Esezobor et al.: Childhood nephrotic syndrome in sub-Saharan AfricaMost nephrologists were managing children/adolescents using
the Kidney Disease: Improving Global Outcomes Guideline
(KDIGO) for Glomerulonephritis. Adult nephrologists used
adult guidelines for adolescents.4 We agreed that the
consensus statement would be applicable in the management
of children younger than age 18 years.
Modification of KDIGO definitions/guidelines
The KDIGO recommendation statements on steroid-
sensitive and steroid-resistant NS and the agreed upon
modifications for low- to middle-income African countries
also were compared with the recently published Interna-
tional Pediatric Nephrology Association guidelines
(Table 2).13
Initial treatment for steroid-sensitive NS. The duration of
the initial prednisone treatment varied considerably, although
most nephrologists followed the recommended duration of 662weeks daily and 6 weeks alternate-day corticosteroid as a
single daily dose (Figure 1a). The majority of nephrologists
used 2 mg/kg or 60 mg/m2 per day to a maximum of 60 mg.
When switching to alternate-day dosing, the majority chose
1.5 mg/kg or 40 mg/m2 per day, to a maximum daily dose of
40 mg (per day) (Table 1).
We agreed to manage the initial episode of NS with oral
prednisone at 60 mg/m2 per day (maximum, 60 mg) as a
single daily dose for 6 weeks, followed by 40 mg/m2
(maximum, 40 mg) prednisone as a single morning dose on
alternate days for another 6 weeks. Prednisone thereafter
should be tapered at a rate of 10 mg/m2 per week to 5 mg on
alternate days (total cumulative dose, 3595 mg/m2 for a total
of 16 weeks). Because the lowest dose available is 5-mg tab-
lets, not suspension, we recommended that all doses be
rounded to up to 5 mg accordingly, and, if at the lowest doseKidney International (2021) 99, 59–67
Figure 1 | Bubble plots show the responses from the survey based on the type of therapy used in nephrotic syndrome by the
duration of use, and the size of the bubble represents the number of responses. (a) Initial prednisone treatment for steroid-sensitive
nephrotic syndrome; (b-d) treatment with steroid-sparing medications.
C Esezobor et al.: Childhood nephrotic syndrome in sub-Saharan Africa po l i c y fo rumof 5 mg, maintain it until the end of the 16th week (different
from KDIGO, in which further tapering is specified).4
Treatment of relapses. Variations in practice also were
noted for treatment of relapses (Table 1). Recommended
treatment for relapses should include oral prednisone 60 mg/
m2 (maximum, 60 mg/d) daily until remission. Once in
remission, we recommend decreasing to 40 mg/m2 per day
(maximum, 40 mg [per day]) on alternate days for 1 week,
and then taper by 10 mg/m2 per day per week to complete a
total of 4 weeks of treatment.
For frequently relapsing (FR)/steroid-dependent (SD)
steroid-sensitive nephrotic syndrome, approximately 90% of
respondents use maintenance alternate-day prednisone for at
least 3 months, with most choosing the lowest dose to
maintain remission. In line with current KDIGO guidelines,
and similar to the protocol described earlier, we recommend
prednisone to treat relapses for up to 3 months at the rec-
ommended relapse dosing.
We agreed to not prescribe prophylactic prednisone for
relapse prevention in children with FR/SDNS already on low-Kidney International (2021) 99, 59–67dose, alternate-day during episodes of malaria, however, we
agreed to use it for upper respiratory infections pending re-
sults of clinical trials.
Use of steroid-sparing agents in FRNS and SDNS. Choice of
steroid-sparing agent, drug route, and dose varied across the
continent, and within each country, as described in Tables 1 and
3 and shown in Figures 1b–d and 2a. Steroid-sparing agents
should be initiated once the patient is in remission, using either
an alkylating agent (cyclophosphamide, chlorambucil), levami-
sole, calcineurin inhibitors (cyclosporine, tacrolimus), myco-
phenolate mofetil, or rituximab, based on availability.
The availability of levamisole varies across the continent. If
available, it is affordable in resource-constrained regions and
in packages of three 40-mg tablets. Doses range from 1.5 to 4
mg/kg, with the most commonly prescribed dose of 2.5 mg/
kg on alternate days (Figures 1b and 2a). Mild to moderate
reversible neutropenia requires monthly monitoring of white
blood cell count. Cost effectiveness, proven efficacy, and a
favorable safety profile supports its use as a steroid-sparing
agent and led the consensus panel to consider levamisole as63




















0.3 0.02 0.01 0.01 0.03 0.013 15.79  28.68
Levamisolem U Generic
50-mg tablets
— — 0.09 — — 0.135 1.39  0.39
Brand name
50-mg tablets
— — 0.16 — 0.01 — 1.05  1.31
Cyclophosphamiden U Generic
25-mg capsules
— — — — — — —
Brand name
50-mg capsules/tablets
0.38 0.31 0.25 0.265 0.50 0.41 6.98  1.89
IV 500 mg
/vial
— 2.20 3.00 5.50 — 2.80 2.32  1.00
1 g/vial — 4.00 4.80 8.00 4.60 4.20 1.76  0.56
Cyclosporineo U U Generic
50 mg
— — 0.83 — 1.30 1.40 58.24  15.06
Brand name 25-mg
tablets
— — 1.84 0.252 1.75 0.69 140.21  97.26
50-mg
tablets
— 1.56 — — 2.60 — 102.96  36.40
100-mg
tablets
— — 7.32 — 2.60 2.00 98.34  72.12
Tacrolimusp U U Generic 0.5-mg
tablets
— — 1.30 — — 0.55 183.15  105.00
1-mg tablets — 2.00 1.72 — — 0.88 151.80  57.70
3-mg tablets — 9.38 — — — — 309.54
5-mg tablets — 10.00 — — — 198.00
Brand name 0.5-mg
tablets
— — — 0.56 2.60 0.67 252.78  227.18
1-mg tablets — — 3.45 2.20 2.60 0.93 227.20  103.82





— 0.354 — — — — 17.51
500-mg
tablets
— 0.416 2.70 0.29 — 1.20 28.48  27.40
Brand name 250-mg
tablets
— — — 0.167 — — 8.26
500-mg
tablets
— 1.875 13.50 — 2.40 1.33 118.13  144.24
FRNS, frequently relapsing nephrotic syndrome; IV, intravenously; SDNS, steroid-dependent nephrotic syndrome; SRNS, steroid-resistant nephrotic syndrome.
aDefined as 2 or more relapses within the first 6 months of diagnosis or 4 or more relapses within any 12-month period.
bDefined as 2 or more relapses during the steroid taper or 1 relapse within 14 days of steroid cessation.
cDefined as no response to steroids within 8 weeks of treatment.
dMultiple medications have different brand names available by country and source of medication; individual names for all countries were not provided. Brand names listed are
from Uganda (Prednisolone: Kam Predisol, Kampala Pharmaceuticals Industries 1996 Limited, Kampala, Uganda; Levamisole: Argotrax [Ergamisole], Agog Pharma Ltd, India;
Cyclophosphamide: Cytoxan, Baxter Healthcare Corporation, Germany; Cyclosporine: Capimune, Mylan, UK; Neoral, Novartis Pharma Services Inc, Germany; Tacrolimus:
Advagraf and Prograf, Astellas Pharma, UK; Mycophenolate Mofetil: Mofilet [Mofetil], Emcure Pharmaceuticals Ltd, India; Cellcept, Roche Pharma, Germany; and Nigeria
[Prednisolone: specific brand available; Levamisole: Argotrax, Agog Pharma Ltd, India; Levamisole: Retrax [not mentioned in the manuscript] manufactured by Reals Group
located in Lagos, Nigeria; Cyclophosphamide: other brands not mentioned in the manuscript available; Cyclosporine: Neoral, Novartis, Switzerland; Tacrolimus: Prograf,
Astellas, Tokyo, Japan; Mycophenolate Mofetil: Teva, Petah Tikva and New Jersey, USA, and Israel; Cellcept, Roche, Basel, Switzerland).
e1 USD is approximately 565 XAF (Central African Franc).
f1 USD is approximately 4.80 GH¢ (Ghanaian Cedi).
g1 USD is approximately 360 ₦ (Naira).
h1 USD is approximately 15 R (South African Rand).
i1 USD is approximately 2285 TZS (Tanzanian Shilling).
j1 USD is approximately 3650 UGX (Uganda Shilling).
kAverage monthly cost was calculated based on a 4-year-old boy at the 50th percentile for height (103 cm) and weight (16.5 kg) based on World Health Organization guideline
growth curves with an estimated surface area of 0.687 m2.
lRoute: oral; dose: 60 mg/m2 per day (maximum daily dose, 60 mg) until remission for 3 days, then 40 mg/m2 per day (maximum daily dose, 40 mg/d), alternate days for 1
week, then taper by 10 mg/m2 per day per week; duration: minimum, 3 days (immediate remission) þ 4 weeks, maximum, number of days it takes to achieve remission þ 4
weeks; monthly cost was calculated based on a full dose daily for 30 days.
mRoute: oral; dose: 2.5 mg/kg alternate days; duration: 6 months to determine effectiveness, if effective, 2 years.
nRoute: oral; dose: 2 mg/kg per day; duration: 3 months; OR route: i.v.; dose: 500 mg/m2 per month; duration: 4 months.
oRoute: oral; dose: 3 to 5 mg/kg per day divided twice daily; duration: 6 months to assess response, up to 2 years; monthly cost was calculated based on 5 mg/kg per day.
pRoute: oral; dose: 0.1 to 0.2 mg/kg per day divided twice daily; duration: 6 months to assess response, up to 2 years; monthly cost was calculated based on 0.2 mg/kg per day.
qRoute: oral; dose: 600 mg/m2 per dose twice daily; duration: 6 months to determine effectiveness, if effective, 2 years.
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C Esezobor et al.: Childhood nephrotic syndrome in sub-Saharan Africa po l i c y fo rumthe first-line, steroid-sparing agent if available.3 Children
should be prescribed levamisole for at least 6 months to
determine its effectiveness, and use for up to 24 months if
effective, allowing for repeated courses.
Cyclophosphamide is efficacious in sustaining a remission
or reducing relapse frequency when given for 8 to 12 weeks.3,6
It typically is used at 2 mg/kg per day. Four sites in Uganda,
Tanzania, Nigeria, and Ghana use intravenous cyclophos-
phamide at 10 to 20 mg/kg per dose (maximum, 750 mg),
owing to hospital funding. Among 17 nephrologists who
prescribe cyclophosphamide, only 3 prescribe it after
inducing remission with prednisone. White blood cell count
is monitored by all centers, on average, every 4 weeks (range,
1–12 wk).
By consensus, cyclophosphamide is the preferred option
for treatment of FR/SDNS if levamisole is not available. The
route of administration depends on access and cost. Intra-
venous cyclophosphamide is an alternative if availability, cost,
or adherence to treatment precludes the use of an oral
formulation. We agreed to oral cyclophosphamide for a
maximum of 12 weeks (total cumulative dose, 168 mg/kg) or
intravenous cyclophosphamide 500 mg/m2 per dose given
monthly for a maximum of 4 months (Figure 1c). We suggest
close monitoring, with complete blood counts within 2 weeks
of therapy, and every 4 weeks thereafter. For intravenous
cyclophosphamide, we recommend complete blood counts
within 1 to 2 weeks of therapy, and before each infusion. We
do not recommend repeated courses of cyclophosphamide.
Cyclosporine is prescribed at a median of 3 mg/kg per dose
twice daily, however, the duration of treatment varies
(Figure 1d). Only 11 of 19 sites perform a kidney biopsy
before starting cyclosporine and only South Africa conducts
surveillance biopsies. Drug monitoring is available in only 3
countries. If measured, target trough levels of cyclosporine
varied from 20 to 100 ng/ml. Although generic tacrolimus is
available, availability across the continent remains limited.
The working group chose cyclosporine as the calcineurin
inhibitor of choice, and recommend its use for a minimum of
6 months to assess response, for up to 24 months with
monthly serum creatinine measurements, and, if possible,
cyclosporine 12-hour trough level monitoring targeting 50 to
100 ng/ml. Relapses after discontinuation of cyclosporine may
occur, therefore, if possible, we recommend a kidney biopsy
before reinitiating cyclosporine, to assess for nephrotoxicity.
The working group agreed to use mycophenolate mofetil
when other steroid-sparing agents have failed. We agreed to
use 600 mg/m2 per dose twice a day with a minimum trial of
6 months to determine responsiveness and continue for up to
24 months of therapy. Repeated courses with mycophenolate
mofetil can be used. We agreed to monthly monitoring of
white blood count.
Use of immunosuppressive agents in steroid-resistant
nephrotic syndrome. Consistent with KDIGO guidelines,
steroid resistance was reported as the lack of response to
treatment after 8 weeks of therapy by 40% of participants
(Figure 2b).Kidney International (2021) 99, 59–67The duration of the calcineurin inhibitor varied consid-
erably from 3 months to as long as 48 months, and in some
centers in combination with low-dose prednisone. If children
relapsed while on therapy, prednisone often was used to
induce remission. Some centers still use cyclophosphamide
owing to low cost and availability, despite contrary evidence.6
The working group agreed that the drug of choice for steroid-
resistant nephrotic syndrome (SRNS) is a calcineurin inhib-
itor, with a similar dosing regimen and duration for FRNS,
but not cyclophosphamide.
Kidney biopsies are performed in children with steroid
resistance in most centers. Nine centers outsource pathology
review to countries within and outside of Africa. All centers
agreed that a biopsy should be performed in children with
SRNS, even though not routinely accessible.4 Treatment of
SRNS should be guided by biopsy findings based on light,
immunofluorescent, and electron microscopy, however, the
working group agreed that light microscopy with special
immunohistochemistry stains may be used if immunofluo-
rescence and electron microscopy are unavailable (Table 2).
Kidney biopsy reports should include the extent of glomer-
ulosclerosis and interstitial fibrosis.
DISCUSSION
International guidelines apply evidence-based medicine to
clinical practice with the goal of improved patient outcomes,
however, there are region-specific limitations and low-
resource–setting issues that need to be considered.
Significant variations in all aspects of clinical practice exist in
management of childhood NS among African nephrologists, both
between and within participating African countries. The main
differences were order of choice for steroid-sparing agents for the
treatment of SRNS, and use of intravenous cyclophosphamide for
the treatment of FR/SDNS because of financial constraints. Some
aspects of care did not align with best available evidence because
approximately 40% of nephrologists prescribed cyclophospha-
mide for SRNS despite well-documented evidence of ineffective-
ness in the treatment of SRNS. This practice is driven mainly by
cost and availability, key factors in decision making.3 Designation
of the child’s age for care by a pediatric nephrologist is based on
the health care system and can greatly affect the initial steroid
management. Recent randomized clinical trials and systematic
reviews do not support a longer initial prednisone course, how-
ever, African children were not included in these trials
(Supplementary Tables S1 and S2).
For the treatment of the initial episode of NS, consensus was
in agreement with the International Pediatric Nephrology As-
sociation guidelines for the dose and duration of steroids. The
consensus to define steroid resistance as a lack of response to
daily prednisone after 8 weeks was based on the possible issues
of adherence or access to medications in Africa. This definition
does vary from the new International Pediatric Nephrology
Association Guidelines on SRNS, which recommends con-
firming SRNS if no remission is achieved by 6 weeks.13
Variations in the duration of steroid therapy before diag-
nosis of SRNS may explain the wide range of steroid65
Figure 2 | (a) Steroid-sparing agents in order of most commonly used to least commonly used are cyclophosphamide, levamisole,
calcineurin inhibitors, MMF, and chlorambucil. Cyclophosphamide is used in the majority of centers. Chlorambucil is not available in
Uganda, Tanzania, Ghana, or Cameroon, it is used primarily in South Africa and in a few clinical sites in Nigeria. Levamisole is not available in
Ghana or Cameroon, and is used more routinely in Nigeria, Tanzania, and Uganda. Cyclosporine is the most commonly used calcineurin
inhibitor (CNI). MMF is available only in Uganda, Tanzania, Nigeria, and South Africa. (b) African nephrologists used varying definitions for
steroid resistance, ranging from 4 to 52 weeks of nonresponse to prednisone, with a median of 8 weeks. IQR, interquartile range.
po l i c y fo rum C Esezobor et al.: Childhood nephrotic syndrome in sub-Saharan Africaresistance rates reported within and across countries in Af-
rica.7–9 Absence of consensus in NS management makes it
difficult to study meta-data on the natural history of NS in
African children. The consensus meeting also provided a
venue for practicing African nephrologists to be engaged in
the process, promoting ownership and collaboration, which
may improve acceptance and adherence to the guidelines,
while improving clinical practice and care for African chil-
dren. We also included adult nephrologists who manage ad-
olescents as young as 12 years old depending on the region
and country.
Adaptability of international protocols to meet local needs,
especially in sub-Saharan Africa where health resources are
limited and most people pay out of pocket, cannot be over-
emphasized. Access to steroid-sparing agents, specifically generic
formulations, is important. There is no consistency among Af-
rican countries in purchasing medications en bloc because health
insurance is almost nonexistent. With the high cost of medi-
cations and drug monitoring, most families are unable to afford
or sustain these drugs. Lack of facilities and personnel for
processing and interpretation of kidney biopsies is a major
impediment throughout Africa, and needs to be addressed.
Consensus agreement on the management of NS for sub-
Saharan Africa will greatly enhance the adoption of treatment
guidelines and may be generalizable to other low-resource
regions. The Ibadan consensus guideline on NS will
improve the quality of care of children with standardized
definitions, pragmatic approaches to dosing and tapering, and
a unified consensus on the use, order, and dose of steroid-
sparing agents.METHODS
We addressed all the KDIGO guidelines for childhood NS for
steroid-sensitive nephrotic syndrome in children (chapter 3 of the66KDIGO guidelines), and steroid-resistant nephrotic syndrome in
children (chapter 4 of the KDIGO guidelines).14 We did not address
nephrotic syndrome in adults.
We invited all the H3A-KDRN participating physicians to com-
plete a short survey regarding current clinical management of NS in
both children and adolescents. All potential participants were con-
tacted by email to complete a 10-minute survey. The practicing
nephrologists completed the survey to determine variability in
practice patterns and the definitions used. Some completed the
survey as an individual or on behalf of the center because of their
common group practice. The survey was sent to 50 nephrologists
from 6 countries and 30 completed the survey. Because children
older than the age of 12 to 18 often are managed by adult ne-
phrologists, we also included 4 adult nephrologists and 6 combined
adult and pediatric nephrologists. We had a 60% response rate for
the survey, however, with some nephrologists reporting on behalf of
the center, the overall response was 95% across 19 participating
centers. The consensus meeting occurred in Ibadan, Nigeria, during
the H3A-KDRN 2018 Annual Investigator and Research Team
Meeting in January 2018. Each survey question was discussed until
consensus was reached. Participants were given equal opportunity to
speak and explain their selected responses. In addition, we included
3 faculty who provided the evidence for each guideline statement and
reviewed current practice. We used the modified Delphi approach,
with repeated rounds of questions and prioritization of statements,
to reach consensus on management of NS. An independent senior
nephrologist moderated the consensus meeting and if there was no
consensus reached, a vote with a simple majority was conducted.
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Figure S1. The survey was completed by 30 nephrologists who
received nephrology training either in or outside Africa (mean years
of training, 3.0  1.7) and who have been practicing as a consultant
nephrologist for a median of 12 years (IQR, 8–15 y). Some completed
the survey for a single center due to common practice.
Table S1. Evidence table for childhood nephrotic syndrome RCT’s.
Table S2. Systematic reviews nephrotic syndrome in children.
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